Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations

Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations

Introduction Alzheimer’s disease (AD) is one of the most common causes of dementia. Pathogenic variants in the presenilin 1 (PSEN1) gene are the most frequent cause of early-onset AD. Medications for patients with AD bearing PSEN1 mutation (PSEN1-AD) are limited to symptomatic therapies and no estab...

Full description

Bibliographic Details
Main Authors: Hidekazu Tomimoto, Takayuki Kondo, Yoshihide Sunada, Hidehiro Ishikawa, Akihiro Shindo, Yuishin Izumi, Haruhiko Banno, Satoshi Morita, Koji Fujita, Ryosuke Takahashi, Haruhisa Inoue, Takakuni Maki, Toshifumi Watanabe, Kenji Ishii, Manabu Ikeda, Taro Okunomiya, Yoko Amino, Kayoko Endo, Akiyoshi Nakakura, Akemi Kinoshita, Harue Tada, Ken Yasuda, Yosuke Taruno, Takashi Suehiro, Kohji Mori, Kazutomi Kanemaru, Kazue Shigenobu, Yumiko Kutoku, Shinobu Kawakatsu, Shunji Shiota, Osamu Uchikawa
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/6/e051343.full

Internet

https://bmjopen.bmj.com/content/11/6/e051343.full

Similar Items